Novartis Q4 Profit Down, Sales Rise; Sees Higher Sales In FY26

Novartis reported mixed Q4 results: net income fell 15% to $2.40 billion ($1.26 EPS) versus $2.82 billion ($1.42 EPS) a year earlier, while core net income was $3.89 billion with core EPS of $2.03 (up from $1.98). Net sales were $13.34 billion, up 1% nominally but down 1% on a constant-currency basis, pressured by US generic erosion and revenue deduction adjustments. The board proposed a 2025 dividend of CHF 3.70 per share (+5.7%), and for fiscal 2026 management guides to low-single-digit net sales growth but expects core operating income to decline low-single-digit, indicating margin pressure ahead despite modest top-line expansion.

Analysis

Market structure: Q4 shows Novartis (NVS) facing US generic erosion and revenue deduction pressure while maintaining modest top-line growth and a 5.7% dividend hike. Winners are payers and low-cost generic/biosimilar producers (e.g., TEVA, VTRS) and bond buyers if dividend supports equity floor; losers are margin-exposed branded/generics hybrids like NVS and any suppliers tied to Sandoz. FX moved from a tailwind to neutral (net sales +1% but -1% cc), signaling fragile pricing power in the US market over the next 12 months.

Risk assessment: Tail risks include a larger-than-expected US generic wave, adverse Medicare/Medicaid pricing reform, or a regulatory setback/impairment that could cut core operating income >5% vs guidance (low single-digit). Immediate risk (days) is a 3–8% sentiment drop around guidance; short-term (3–6 months) is margin compression from rebate/revenue adjustments; long-term (12–36 months) hinges on Sandoz turnaround and pipeline launches. Hidden dependency: revenue deductions (rebates/returns) can swing free cash flow two-quarters forward, so monitor working capital and receivables.

Trade implications: Tactical direct plays: establish a small opportunistic short of 1–2% NAV in NVS for 3 months, stop at +6% adverse move, target -8% downside if guidance deterioration continues. Pair trade: long 1.5% NAV RHHBY/ROG (or AZN) vs short 1.5% NVS to capture relative operational resilience over 6–12 months. Options: for holders, sell 3-month covered calls to harvest premium + dividend; buy 12-month 10% OTM puts as tail protection if exposure >3%.

Contrarian angles: The market may be over-discounting Novartis’ ability to stabilize Sandoz — if Sandoz EBITDA stabilizes within 6–12 months or core operating income decline stays <3%, NVS could re-rate; consider accumulation on an 8–12% share-price pullback or if forward dividend yield rises above 3.8%. Watch catalysts: Sandoz restructuring updates and quarterly revenue-deduction disclosures in the next 60 days — these will be decisive for medium-term conviction.

Key Decisions for Investors

• Establish a tactical 1–2% NAV short position in NVS for a 3-month horizon to capture near-term downside risk from US generic erosion; place stop-loss at a 6% adverse move and target an 8% decline.
• Open a 1.5% NAV long vs 1.5% NAV short pair: long Roche (RHHBY or ROG) and short NVS for 6–12 months to express relative-strength in diagnostics/biologics versus generics exposure.
• If long NVS, sell 3-month covered calls sized to cap upside to +4–6% while collecting premium and the 3.70 CHF dividend; simultaneously buy a 12-month 10% OTM put sized at 25–50% of position for tail protection.
• Reallocate 3–5% portfolio weight away from EU large-cap pharma with high generics exposure (NVS, TEVA) into oncology/diagnostics names (RHHBY/ROG, AZN) over the next 30–90 days; trim further on any confirmation of >3% FY26 core operating income downgrade.
• Accumulate NVS on an 8–12% share-price pullback or if forward dividend yield >3.8%, increasing position up to 2–3% NAV conditional on Sandoz EBITDA stabilization within 6–12 months and no adverse regulatory rulings in next 60 days.